PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

An Expertise and Dedication to Advancing Cell Therapy Manufacturing: An Interview with Camille Bachelet of CELLforCURE by SEQENS

Can you please start by providing a brief overview of CELLforCURE’s history and how the company has
developed since being founded?

Founded in 2010 by LFB, a French government-owned pharmaceutical company, CELLforCURE was created to pioneer manufacturing in the emerging field of cell & gene therapy. Designed as one of the first specialised CDMOs in Europe, CELLforCURE built a GMP facility tailored to ATMP (Advanced Therapy Medicinal Products) production.

In 2015, CELLforCURE reached a major milestone when it received GMP authorisation from the ANSM, allowing it to manufacture ATMPs for both clinical and commercial use in Europe. This recognition positioned CELLforCURE as a trusted manufacturing partner in the growing cell therapy ecosystem. In 2016, CELLforCURE manufactured clinical vials of an allogeneic CAR-T cell therapy, marking one of the first GMP
productions of its kind in Europe.

In 2019, Novartis acquired CELLforCURE and, from 2020 to 2023, CELLforCURE produced the first approved autologous CAR-T therapy. In 2023, following a strategic decision made by Novatis, SEQENS acquired CELLforCURE, marking a new chapter. Now under SEQENS, CELLforCURE continues to deliver end-to-end
CDMO services in ATMP manufacturing from early clinical phases to commercial supply, leveraging more than a decade of operational and regulatory expertise.

Today, CELLforCURE by SEQENS remains one of the key CDMOs in Europe dedicated to the manufacturing of innovative cell and gene therapies.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC